CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 100 enrolled
Drug / intervention
Voclosporin Ophthalmic Solution +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03597139
NCT03597139Phase 2Completed
CompareCT.gov

An Investigator-Masked, Randomized, Parallel-Group Study of the Ocular Tolerability of Voclosporin Ophthalmic Solution Versus Restasis® in Subjects With Dry Eye Disease

Aurinia Pharmaceuticals Inc.·interventional·Posted Jul 24, 2018·Updated Jul 8, 2021

In Brief

A Phase 2 clinical trial evaluating Voclosporin Ophthalmic Solution and Restasis® for Dry Eye. Completed, enrolled 100 participants across 7 sites.

Detailed Summary

Evaluate the tolerability, efficacy and safety of VOS versus Restasis® in subjects with mild to moderate Dry Eye Disease (DED).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJul 24, 2018
Enrollment StartAug 13, 2018
Primary CompletionNov 9, 2018
Study CompletionDec 13, 2018
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 7.9 years ago

Interventions

Voclosporin Ophthalmic Solutiondrug

Investigational Drug

Restasis®drug

Comparator